TickerGuard
Buy Day today: Neutral (55) Mixed market breadth · no major macro event
PALI

Palisade Bio Inc

Healthcare · Biotechnology

1.50$ -2.0% vs. previous close Closing price · As of: Oct 8, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow PALI
Line item 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-235.7% -1,254.9% -1,307.4% – – -1,360.9% -2,072.8% -2,079.4% -9,628.7% -62,160.5% -181,738.2% -96,122.8% -5,160.1% -2,958.6% -47,133.2% -35,266.3% – -5,344.0% -4,453.2% – –
17.3% 19.5% 10.5% – – 17.8% 47.9% 51.8% 222.5% 1,851.2% 3,316.3% 2,077.5% 111.2% 71.5% 934.5% 22.2% – 1.2% 1.6% – –
– 135.4% 514.6% – – 714.6% 853.3% 395.1% 2,119.5% 22,938.8% 28,332.2% 21,208.5% 680.8% 419.2% 21,599.3% 14,896.4% – 412.8% 249.6% – –
– – – – – – – – – – – – – 514.2% 18,072.0% 21,893.5% – – – – –
9.1% -225.5% 1,644.0% – – 845.4% -1,664.7% 1,301.4% 5,260.5% 66,214.1% -21,072.5% 9,303.2% -828.4% -129.6% 1,353.0% 17,670.1% – 500.0% 160.0% – –
5.9% 22.3% 75.0% – – 45.4% 123.1% 62.5% 488.2% 2,954.1% 2,338.3% 991.7% 36.2% 0.7% 39.0% 44.4% – 4.0% 1.6% – –
-5.9% -22.3% -75.0% – – -45.4% -123.1% -62.5% -488.2% -82,641.2% 69,563.6% 14,504.1% -36.2% 1,922.4% 25,472.2% -44.4% – -4.0% -1.6% – –
– – – – – – – – – – – 173,082.4% 3,360.0% 703.1% 42,569.1% 108,714.6% – – 6.8% – –
– – – – – – – – – – – – – 521.9% -1,429.1% 14,622.8% – -316.0% -156.4% – –
399.3% 1,759.0% 3,211.1% – – 2,354.0% 427.1% 3,390.7% 18,658.8% 121,831.0% 37,315.8% 146,120.4% 1,919.5% 697.8% 42,805.7% 13,979.3% – 6,103.2% 4,474.4% – –
– 481.9% 1,828.6% – – 947.8% -1,768.8% 1,248.9% 8,547.5% -22,976.0% -74,901.1% 64,498.4% -3,276.9% -341.5% -4,366.6% -21,331.4% – 755.2% 19.6% – –
-241.6% -1,277.1% -1,382.4% – – -1,406.2% -2,195.9% -2,141.9% -10,117.0% -65,114.6% -184,076.5% -97,114.5% -5,196.2% -2,959.3% -47,133.2% -35,310.7% – -5,348.0% -4,454.8% – –

Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?